Market awaits more direction on Amgen despite positive earnings and guidance
This article was originally published in Scrip
Despite issuing guidance for increased revenue and earnings per share (EPS) for 2013, Amgen's stock price took a small hit in after-hours trading when the company reported 2012 earnings gains on 23 January, but said it wouldn't offer many specifics around its growth strategy beyond currently marketed therapies until February.
You may also be interested in...
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.